Astellas Pharma Inc. acquired Xyphos Biosciences, Inc. to strengthen its immuno-oncology pipeline. With the acquisition Astellas gains Xyphos’ novel and proprietary ACCEL (Advanced Cellular Control through Engineered Ligands) technology platform, as well as...
Astellas
Category
Astellas Pours $13M more into Boston Life Science Cluster Now Totaling over $1B to Date
Astellas Pharma Inc. announced a nearly $13 million investment into two innovation incubators operated by LabCentral, a premier U.S.-based laboratory facility for next-generation biotech startups. Astellas has infused over $1 billion into the Boston-area life...